Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment
出版年份 2017 全文链接
标题
Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment
作者
关键词
-
出版物
JOURNAL OF IMMUNOLOGY
Volume 200, Issue 1, Pages 347-354
出版商
The American Association of Immunologists
发表日期
2017-11-15
DOI
10.4049/jimmunol.1701262
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- (2017) Sacha Gnjatic et al. Journal for ImmunoTherapy of Cancer
- Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
- (2016) Rachel E. Sanborn et al. CANCER RESEARCH
- CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
- (2016) T. Ahrends et al. CANCER RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
- (2016) A. Murtaza et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Multispectral Imaging of T and B Cells in Murine Spleen and Tumor
- (2016) Zipei Feng et al. JOURNAL OF IMMUNOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Multiplexed tissue biomarker imaging
- (2016) Edward C. Stack et al. Journal for ImmunoTherapy of Cancer
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
- (2016) Maarten Swart et al. Frontiers in Oncology
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
- (2015) A. S. Mansfield et al. CLINICAL CANCER RESEARCH
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
- (2015) Venky Ramakrishna et al. Journal for ImmunoTherapy of Cancer
- Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma
- (2015) Zipei Feng et al. Journal for ImmunoTherapy of Cancer
- Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
- (2014) Edward C. Stack et al. METHODS
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- When Tissue Antigens and Antibodies Get Along
- (2013) J. A. Ramos-Vara et al. VETERINARY PATHOLOGY
- A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays
- (2012) Wei Huang et al. HUMAN PATHOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
- (2008) M. J. Gough et al. CANCER RESEARCH
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started